Evoke Pharma (EVOK) Proxy Filing summary

Executive summary

• Annual meeting scheduled for May 21, 2025, to be held virtually for all stockholders of record as of March 24, 2025.

• Proxy materials, including the notice, proxy statement, and annual report, are available online, with paper copies available upon request.

Voting matters and shareholder proposals

• Election of two directors, Malcolm R. Hill and Vickie W. Reed, for a three-year term expiring at the 2028 annual meeting.

• Ratification of BDO USA, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

• Advisory vote on the compensation of named executive officers as disclosed in the proxy statement.

• Advisory vote on the frequency of future say-on-pay votes, with the board recommending every three years.

• Provision to transact other business as may be properly brought before the meeting.

Board of directors and corporate governance

• Board recommends voting for all proposals and supports a three-year frequency for say-on-pay advisory votes.